• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

PMX205 Inhibitor – PMX 205 Trifluoroacetate

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753710

MBS5753710 is an inhibitor targeting PMX205. Also known as PMX 205 Trifluoroacetate. PMX 205 Trifluoroacetate is a potent complement antagonist of C5a receptor. More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
PMX 205 Trifluoroacetate (PMX205), Inhibitor
Full Product Name
PMX 205 Trifluoroacetate
Product Gene Name
PMX205, inhibitor
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
953.06
Solubility
DMSO: 100mg/mL (104.93mM)
H2O: 0.67mg/mL (0.70mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C47H63F3N10O8
SMILES
OC(C(F)(F)F)=O.O=C([C@H](NC([C@@]1([H])N(CCC1)C([C@](NC(CCC2=CC=CC=C2)=O)([H])CCCNC([C@H](CCCNC(N)=N)NC3=O)=O)=O)=O)CC4CCCCC4)N[C@@]3([H])CC5=CNC6=CC=CC=C56
Target & IC50
Others
In Vitro
oral delivery of a cyclic hexapeptide C5a receptor antagonist (PMX205) for 2-3 mo resulted in substantial reduction of pathological markers such as fibrillar amyloid deposits (49-62%) and activated glia (42-68%) in two mouse models of AD. The reduction in pathology was correlated with improvements in a passive avoidance behavioral task in Tg2576 mice. In 3xTg mice, PMX205 also significantly reduced hyperphosphorylated tau (69%). These data provide the first evidence that inhibition of a proinflammatory receptor-mediated function of the complement cascade (i.e., C5aR) can interfere with neuroinflammation and neurodegeneration in AD rodent models, suggesting a novel therapeutic target for reducing pathology and improving cognitive function in human AD patients[3].

Structure of PMX205, inhibitor

PMX205 Inhibitor – Cat# MBS5753710

Product References and Citations for PMX205, inhibitor

Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment, J Cancer Res Ther. 2016 Apr-Jun;12(2):590-6.
Kosni NN, et al. Expression of complement C5a receptor and the viability of 4T1 tumor cells following agonist-antagonist treatment, J Cancer Res Ther. 2016 Apr-Jun;12(2):590-6.
Woodruff TM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34.
Woodruff TM, et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34.
Fonseca MI, et al. treatment,with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009 Jul 15;183(2):1375-83.
Fonseca MI, et al. treatment,with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol. 2009 Jul 15;183(2):1375-83.

Other Notes

Small volumes of PMX205, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000